2024 Chongqing Precision Biotech Co., Ltd.

Cn
En

More years

The 10th Indication Approved! Precision Biotech Announces Clinical Trial Approval from NMPA for MC-1-50 for Treatment of its First Autoimmune Disease Indication -Systemic Lupus Erythematosus (SLE)

On December 6, 2024, Chongqing Precision Biotech’s self-developed MC-1-50 cell preparation obtained clinical trials approval from the Center for Drug Evaluation (CDE) of the NMPA

The Groundbreaking Ceremony for Chongqing Precision Biotech Cell Technology Research and Development Center and Cell Preparation Center Was Successfully Completed

On November 8, 2024, the groundbreaking ceremony for Chongqing Precision Biotech Cell Technology R&D and Cell Preparation Center project was held in the Western Science City, Chongqing High-tech Zone.

Delegation from Kimbiri of Peru and the President of Tashkent Pharmaceutical University Visited Chongqing Precision Biotech

Delegation from Kimbiri of Peru and the President of Tashkent Pharmaceutical University Visited Chongqing Precision Biotech

Exclusive Interview with Professor Qian Cheng, Chairman of Precision Biotech: Successfully Broken through the CAR-T Track, and the First Domestic CAR-T cell Drug for Pediatric Leukemia Is about to Be Approved

Exclusive Interview with Professor Qian Cheng, Chairman of Precision Biotech: Successfully Broken through the CAR-T Track, and the First Domestic CAR-T cell Drug for Pediatric Leukemia Is about to Be Approved

Chongqing Precision Biotech’s First IND Application for CAR-T therapy in Autoimmune Diseases has been Accepted by CDE

Exclusive Interview with Professor Qian Cheng, Chairman of Precision Biotech: Successfully Broken through the CAR-T Track, and the First Domestic CAR-T cell Drug for Pediatric Leukemia Is about to Be Approved

Another Weighty Honor! Precision Biotech Selected for "Kechuang China" New Sharp Enterprise List

On July 2nd, China Association for Science and Technology released the list of "Kechuang China" in 2023 at the 26th annual meeting.

Chongqing Precision Biotech Announced the NMPA Acceptance of the New Drug Application for Priscabtagene Autoleucel Injection, China’s first CAR-T Product For The Treatment of Childhood Leukemia

On July 20, 2024,Chongqing Precision Biotech Announced the NMPA Acceptance of the New Drug Application for Priscabtagene Autoleucel Injection.

Professor Qian Cheng, Chief Scientist of Chongqing Precision Biotech, Awarded "Top Ten Scientists for Drug Innovation"

On June 20th, the high-profile 4th Annual Selection and Awarding Conference of Drug Innovation Award was held in Shanghai.

Chongqing Precision Biotech Announced its Clinical Breakthrough in Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

From May 31-June 4, 2024 the American Society of Clinical Oncology (ASCO) was held in Chicago, USA.

Previous 1 2 Next

FOLLOW US ON WECHAT

© Copyright 2016-2024 重庆精准生物技术有限公司 All Rights Reserved

渝ICP备16003030号-1

渝公网安备 50010702505019号

Design By:zhiing